Widespread Statin Use Not Recommended in Old, Very Old

Share this content:
Widespread Statin Use Not Recommended in Old, Very Old
Widespread Statin Use Not Recommended in Old, Very Old

THURSDAY, Sept. 6, 2018 (HealthDay News) -- Statin use is not associated with reduced risk of atherosclerotic cardiovascular disease (CVD) or all-cause mortality among older adults without type 2 diabetes, according to a study published online Sept. 5 in The BMJ.

Rafel Ramos, M.D., Ph.D., from the Institut Universitari d'Investigació en Atenció Primària Jordi Gol in Catalonia, Spain, and colleagues conducted a retrospective cohort study involving 46,864 participants aged 75 years or older without clinically recognized atherosclerotic CVD.

The researchers found that among participants without diabetes, the hazard ratios for statin use in 75- to 84-year-olds were 0.94 (95 percent confidence interval [CI], 0.86 to 1.04) and 0.98 (95 percent CI, 0.91 to 1.05) for atherosclerotic CVD and all-cause mortality, respectively; for those aged 85 years and older, the corresponding hazard ratios were 0.93 (95 percent CI, 0.82 to 1.06) and 0.97 (95 percent CI, 0.90 to 1.05). Among those with diabetes, the corresponding hazard ratios for statin use were 0.76 (95 percent CI, 0.65 to 0.89) and 0.84 (95 percent CI, 0.75 to 0.94) in those aged 75 to 84 years, and 0.82 (95 percent CI, 0.53 to 1.26) and 1.05 (95 percent CI, 0.86 to 1.28) for those aged 85 years and older.

"These results do not support the widespread use of statins in old and very old populations, but they do support treatment in those with type 2 diabetes younger than 85 years," the authors write.

Abstract/Full Text
Editorial

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

CDC: Increase Seen in Salmonella Illnesses From Ground Beef

CDC: Increase Seen in <i>Salmonella</i> Illnesses From Ground ...

246 people now sickened; 59 people have been hospitalized; no deaths reported to date

Epinephrine Personal Autoinjectors Cost-Effective at 24

Epinephrine Personal Autoinjectors Cost-Effective at &#36;24

Based on 10-fold fatality risk difference, value-based price for personal epinephrine $24

Burden of Liver Cancer Rising in Medicare Patients

Burden of Liver Cancer Rising in Medicare Patients

Coexistence of other liver conditions tied to even higher risk for death, health care costs

is free, fast, and customized just for you!




Already a member?

Sign In Now »